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ABSTRACT
The immune system plays an essential role in eradicating cancer in concert with various treatment
modalities. In the absence of autologous tumor material, no standardized method exists to assess T cell
responses against the many antigens that may serve as cancer rejection antigens. Thus, development of
methods to screen for therapy-induced anti-tumor responses is a high priority that could help tailor
therapy. Here we tested whether a tumor-derived antigen source called DRibbles , which contain a pool
of defective ribosomal products (DRiPs), long-lived and short-lived proteins (SLiPs) and danger-associated
molecular patterns (DAMPs), can be used to identify tumor-associated antigen (TAA)-specific responses in
patients before or after immunotherapy treatment. Protein content, gene expression and non-
synonymous – single nucleotide variants (ns-SNVs) present in UbiLT3 DRibbles were compared with
prostate adenocarcinomas and the prostate GVAX vaccine cell lines (PC3/LNCaP). UbiLT3 DRibbles were
found to share proteins, as well as match tumor sequences for ns-SNVs with prostate adenocarcinomas
and with the cell lines PC3 and LNCaP. UbiLT3 DRibbles were used to monitor anti-tumor responses in
patients vaccinated with allogeneic prostate GVAX. UbiLT3-DRibble-reactive CD8C T-cell responses were
detected in post-vaccine PBMC of 6/12 patients (range 0.85–22% of CD8C cells) after 1 week in vitro
stimulation (p D 0.007 vs. pre-vaccine). In conclusion, a cancer-derived autophagosome-enriched
preparation, packaging over 100 proteins over-expressed in prostate cancer into microvesicles containing
DAMPs, could be used to identify CD8C T cells in peripheral blood from patients after prostate GVAX
vaccination and may represent a general method to monitor anti-cancer T cell responses following
immunotherapy.
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Introduction
Tumor cells express self and altered-self proteins (neo-anti-
gens) and present these to the immune system by means of
MHC-peptide complexes. The majority of the peptides that are
presented on tumor human leukocyte antigen (HLA) molecules
are likely derived from short-lived proteins (SLiPs) and defec-
tive ribosomal products (DRiPs) bound to HLA and trans-
ported to the cell surface.1-3 While these peptides may be
readily presented by the tumor cells, the immune system has
been poorly educated to recognize these, since these rapidly
degraded products are less likely available for cross-
presentation by professional antigen presenting cells (APCs)
such as dendritic cells (DCs). Hence, the peptide repertoire that
DCs use to prime the adaptive immune system might not be
representative of the dominant epitopes tumor cells actually
present, resulting in poor tumor-cell recognition. Moreover, in
the presence of tumor-induced suppression, function of both
DCs and T cells can be hampered, further compromising elimi-
nation of tumor cells by the immune system.4,5 Many immuno-
therapy regimens aim to convert the tolerant tumor
microenvironment into an immune stimulatory one, thereby
promoting tumor cell recognition and killing.6,7
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Primary and metastatic prostate cancers have been charac-
terized by sequencing, copy-number alteration and expression
profiling.8,9 Recently, 333 primary prostate cancers were char-
acterized and found to have an overall mutation burden of 0.94
mutations/Mb (median, range 0.04–28 per megabase), a lower
mutation burden than many other epithelial tumors.8,10 150
metastatic prostate cancers were found to have an overall muta-
tion rate of 4.4 mutations/Mb, though some had nearly 50
mutations/Mb9. We hypothesize that immune responses that
develop in patients with objective clinical responses upon
immunotherapy treatment are directed against a wide variety
of antigenic determinants overexpressed by their cancer. In the
case of prostate cancer, we reported that a patient, who experi-
enced a complete response following treatment with ipilimu-
mab, developed strong humoral immune responses against a
number of proteins that had not been identified previously as
possible tumor antigens. This included one protein, HIBCH,
strongly over-expressed by the patient’s tumor and found to be
mutated in 5 percent of prostate cancers.11 In another study,
patients with prostate cancer that experienced a clinical
response following treatment with GM-CSF and ipilimumab,
exhibited some shared antibody responses, and a CD4 T cell
response was detected against one of these shared proteins,
PAK6.12 Neither HIBCH nor PAK6 had previously been con-
sidered to be tumor-associated antigens. While the concept
that mutations or non-synonymous single nucleotide variants
(ns-SNVs) in random proteins can serve as tumor-rejection
antigens has been described, and is driving significant enthusi-
asm for novel immunotherapy strategies,13-17 this is in part a
consequence of knowing the neo-epitopes present in a specific
tumor and looking for an immune response against those anti-
gens. While clearly an important step, this approach excludes
the possibility of detecting immune responses against SLiPs/
DRiPs and a spectrum of proteins known to be over-expressed
by cancers, including many that were “prioritized” by a
National Cancer Institute panel based on parameters that
included known immunogenicity and in some cases, associa-
tion of immune responses with therapeutic effects.18 While pro-
tein arrays are allowing an evaluation of humoral immunity
against more than 15,000 proteins,12,19 our ability to monitor T
cell immunity has not kept pace. In 2017, the generally applied
immune monitoring strategies focus on identifying responses
against selected well-known antigens, the specific antigen(s)
used as a vaccine or, when tumor sequence data is available,
evaluate for response to possible neo-epitopes.20 These
approaches will miss immune responses against other over-
expressed targets, whether or not they are mutated, will
generally miss epitope spreading, and might underestimate the
magnitude of the induced anti-cancer immune response.
Our lab developed autophagosome-enriched vaccines,
called DRibbles, which are generated from tumor cells or
cell lines through inhibition of proteasomal degradation
and lysosomal fusion. This results in accumulation of pro-
teins including SLiPs and DRiPs in stable double-mem-
brane autophagosomal vesicles that are isolated through
cell disruption and differential centrifugation.21-24 A human
allogeneic autophagosome vaccine, DPV-001, comprising
DRibbles derived from an adenocarcinoma (UbiLT6) and a
mixed histology adenocarcinoma/squamous cell cancer
(UbiLT3) cell line, has recently been tested in a randomized
multi-center Phase II study for adjuvant treatment of defin-
itively treated stage IIIA/B NSCLC patients and a pilot
study for men with advanced prostate cancer.24 Gene
expression analysis of the two cell lines, UbiLT3 and
UbiLT6, revealed that they highly express genes for a wide
range of antigens common to adenocarcinomas and squa-
mous cancers (unpublished data).
While allogeneic DRibbles are not designed to encompass
patient-specific neo-epitopes, whole exome-sequencing (WES)
analysis identified sequences in the UbiLT3 and UbiLT6 cell
lines that match the tumor sequence for a wide variety of tumor
somatic mutations. Additionally, the potential of ns-SNVs to
generate altered peptide ligands, may help break tolerance
against non-altered proteins that are over-expressed by a
patient’s cancer.25 In some cases, the vaccine, or monitoring
agent (in this case UbiLT3 DRibbles) may match some ns-SNV
somatic mutations. In addition, in vitro analyses showed that
DRibbles derived from the UbiLT3 cell line contain agonist
activity for multiple Toll-like receptors (TLRs (TLR-2,-3,-4,-7,-9)
(TLH unpublished data), which can promote the activation of
DCs and monocytes.26 In this study, we analyzed transcript lev-
els for antigens over-expressed in prostate cancers compared to
the patients’ normal tissue (The Cancer Genome Atlas (TCGA)
PRAD Provisional database – 498 samples) for which protein
was confirmed to be present in the UbiLT3 DRibble vaccine.
We anticipated, also based on our in vivo mouse studies, that
APCs would be required for the processing and cross-presenta-
tion of the DRibble-derived antigens,22,23,27 allowing this
approach to be used for all patients and not being restricted to
HLA-A2C patients, as is often the case for peptide-based moni-
toring approaches. This is, to our knowledge, the first report in
which human tumor cell-line derived autophagosomes are used
to monitor responses against non-viral antigens in human
patient samples. Our data show that in some but not all prostate
GVAX treated patients, IFN-g producing CD8C T cells could be
identified in post vaccine PBMC after one week in vitro-stimula-
tion with UbiLT3 DRibbles.
Results
Identification of overlapping gene expression, ns-SNVs and
protein between UbiLT3 DRibbles and Prostate cancers
In order to determine whether the well-characterized UbiLT3
DRibble product could be used to monitor vaccine-induced
anti-tumor T-cell responses in clinical samples from prostate
cancer patients, we identified overlapping gene expression and
protein products between prostate adenocarcinomas, UbiLT3
DRibbles, and the GVAX vaccine cell lines (PC3 and LNCaP).
As is common for patients with metastatic prostate cancer, no
material was available for gene expression analysis. Instead,
publically available gene expression profiles, and ns-SNVs in
prostate cancers compared to patients’ normal tissue, were
obtained from TCGA. Mass spectrometry identified 5286 pro-
teins in UbiLT3 DRibbles. Gene expression data (RNA-Seq)
was available in TCGA prostate adenocarcinoma (PRAD) pro-
visional database for 5233 of the proteins. Proteins confirmed
to be present in UbiLT3 DRibbles by mass spectrometry were
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queried (http://www.cbioportal.org/public-portal/) against gene
expression data (z score §2) for PRAD cases (n D 498) to
identify the degree of overlap between genes overexpressed in
tumor specimens compared to the patients’ normal tissue and
proteins in DRibbles used to monitor T-cell responses (average
D 235.2 genes) (Fig. 1A). Every patient’s tumor over-expressed
genes for which the protein is in UbiLT3 DRibbles, with 329 of
498 tumors over-expressing more than 100 genes coding for
proteins confirmed to be present in UbiLT3 DRibbles. PRAD
tumors overexpressed (z-score  2) an average of 734.5 genes,
with a range from 57–2975. UbiLT3 DRibbles contained an
average of 235.2 of the overexpressed genes per patient sample,
range 5–1327. In samples categorized as having evidence of
metastasis in the associated clinical data, the average number of
overexpressed genes contained in UbiLT3 DRibbles increased
to 330 (data not shown). The percent of overexpressed genes
present in UbiLT3 ranged from 4% to 61%. There were at least
81 proteins identified in UbiLT3 DRibbles where the gene is
over-expressed in 10% of the TCGA PRAD samples (z-score
 2). Publically available gene expression data for the LNCaP
and PC3 cell lines (TCGA, CCLE microarray) showed overex-
pression (z-score  2) of 5 and 24 of those genes, respectively
(Supplemental Table S1).
Since epitopes derived frommutations might be more immu-
nogenic due to the creation of neo-epitopes, whole exome-
sequencing data of the UbiLT3 cell line was compared to ns-
SNVs identified in available prostate adenocarcinoma samples
and PC3/LNCaP WES databases. Whole exome sequencing of
the UbiLT3 cell line identified ns-SNVs in UbiLT3 with respect
to the hg19 reference genome (9532 ns-SNVs; 1342 ns-SNVs fil-
tered with (hg19) dbsnp (common) variants). VCF files for 307
specimens in the TCGA PRAD provisional database of exome-
Figure 1. Tumor-antigen overlap between the UbiLT3 DRibbles and Prostate cancer specimens in the TCGA database. A. Over-expressed genes (z-score2) from RNA-Seq
expression data on 498 prostate adenocarcinoma tumor specimens, compared to the patients’ normal tissue (TCGA), analyzed for overlap with proteins identified in
UbiLT3 DRibbles by mass spectrometry. B. Mutation data from WES of 307 prostate adenocarcinoma specimens (TCGA) for ns-SNVs in tumor specimens with respect to
the patients’ normal tissue was compared to the sequence of UbiLT3 for UbiLT3 sequences matching the tumor sequence. C. PC3 cell line sequences matching sequence
overlap between UbiLT3 and PRAD ns-SNVs in panel B. D. LNCaP cell line sequences matching sequence overlap between UbiLT3 and PRAD ns-SNVs in panel B.
ONCOIMMUNOLOGY e1466766-3
sequenced tumors were analyzed to determine unique ns-SNVs
in tumor specimens with respect to the patients’ normal tissue.
Unique ns-SNVs were compared to the UbiLT3 sequence to
identify potential mutations matching the UbiLT3 sequence
using CLC Genomics Workbench 7.5 (Average D 44.38)
(Fig. 1B). Ns-SNVs were identified in all specimens where
UbiLT3 matched the unique tumor sequence, with a range from
9 to 256. VCF files for PC3 and LNCaP cell lines were compared
to the TCGA PRAD provisional database (Fig. 1C) for shared
ns-SNVs (PC3 AverageD 28; Range 1–234 and LNCaP Average
D 59.6; Range 14–340 shared ns-SNVs). UbiLT3 and PC3 or
UbiLT3 and LNCaP sequences were compared to PRAD speci-
mens to identify corresponding ns-SNVs (Fig. 1D). PRAD speci-
mens had an average of 11.23 ns-SNVs found in PC3 and
UbiLT3. Shared ns-SNVs ranged from 0 to 108. PC3 and
UbiLT3 shared 3067 ns-SNVs (254 ns-SNVs filtered with (hg19)
dbsnp (common) variants). PRAD specimens had an average of
15.34 ns-SNVs found in both LNCaP and UbiLT3. Shared ns-
SNVs ranged from 0 to 148. LNCaP and UbiLT3 shared 4306
ns-SNVs (419 ns-SNVs filtered with (hg19) dbsnp (common)
variants). UbiLT3 DRibbles contain 847 proteins covering 1310
of 6407 ns-SNVs present in PC3. 468 proteins cover 633 out of
the 3067 ns-SNVs shared between PC3 and UbiLT3. 1745
UbiLT3 DRibble proteins cover 2881 of 11938 ns-SNVs present
in LNCaP. 651 proteins cover 893 of 3067 ns-SNVs shared
between LNCaP and UbiLT3. The mutation status of proteins
identified by mass spectrometry and antigenicity/processing of
mutations and ns-SNVs has yet to be determined.
Shared TAA in UbiLT3 DRibbles can be recognized by CD8C
T cells post prostate GVAX vaccination
The protein overlap and the presence of relevant ns-SNVs in
DRibbles generated from the UbiLT3 cell line and the genes
over-expressed by prostate cancers, prompted us to test
whether UbiLT3 DRibbles could be used to detect tumor-anti-
gen-specific T cells in blood samples from patients with pros-
tate cancer. As a control, DRibbles were prepared from human
primary kidney cells using the same protocol.
To test whether UbiLT3 DRibbles could be used to mon-
itor the generation of a cancer-vaccine induced immune
response, we isolated PBMC from patients with metastatic
CRPC, who were vaccinated with prostate GVAX. From the
17 patients included in this trial, post GVAX PBMC sam-
ples (week 12) were available from 12/17 patients. No
objective clinical responses were observed in any of the
patients treated on this trial. These patients were very sick
and did not receive any checkpoint blockade in addition to
the prostate GVAX vaccine to overcome tumor-induced
immune suppression.28,29 Two patients in cohort C and one
patient in cohort B displayed an increase in prostate-specific
antigen doubling time (PSA-DT) post-treatment, suggestive
of reduced tumor growth. Additional clinical assessment
and immune monitoring performed for this trial will be
described elsewhere (Curti et al., and Puri et al. manuscripts
in preparation).
As an initial screen, pre- and post treatment PBMC from
four patients were cultured ex vivo in the presence of 25mg/ml
DRibbles derived from normal kidney cells (NK) or UbiLT3 or
vehicle control for 40 hours, after which supernatants were har-
vested and IFN-g secretion was assessed (Fig. 2A). No IFN-g
was detected in supernatants from pre-vaccine PBMC (data
not shown), but IFN-g secretion was detected in 3 out of 4
post-vaccine PBMC samples upon incubation with UbiLT3
Dribbles, but not vehicle, or NK DRibbles. In this experiment,
the 3 patients in whom IFN-g secretion was detected upon cul-
ture with UbiLT3 DRibbles also displayed increased or stabi-
lized PSA-DT upon therapy (PSA-DT of 1.0, 1.3 and 3.4, for
patients 9, 10 and 12, respectively).
Next, we tested whether stimulation with UbiLT3 DRib-
bles induced IFN-g producing CD8C T cells. In order to
increase the chance of detecting robust CD8C T cell
responses, a one-week in vitro stimulation protocol was
applied. Of the twelve evaluable patients, IFN-g producing
CD8C T cells responsive to antigens present within UbiLT3
DRibbles could be identified in in vitro-stimulated post-vac-
cine samples from 6/12 patients with a mean of 7.1% IFN-gC
CD8C T cells (range 0.85-22%) (Fig. 2B and C). IFN-g pro-
ducing CD8C T cells were never observed in pre-vaccine
PBMC or in post-vaccine PBMC stimulated with vehicle or
NK DRibbles as primary stimulus followed by re-stimulation
with UbiLT3 DRibbles (Fig. 2B) or NK DRibble prime/boost
(Fig. 2C). UbiLT3-responding CD8C T cells were not
detected in healthy donor (HD) PBMC, suggesting that these
CD8 responses were vaccine induced and therefore likely to
recognize antigens present in the UbiLT3 DRibbles (Fig. 2C).
CD8C T-cell responses to UbiLT3 DRibbles in the patients
tested were independent of the treatment arm, since the
patients with a CD8 response to UbiLT3 Dribbles were pres-
ent in all three arms (Fig. 2B). There was no correlation
between PSA-DT increase or decrease upon treatment and
the ability to generate UbiLT3-recognizing IFN-g producing
CD8C T cells, nor was there a prevalence for a specific HLA-
type amongst the responding patients or an overlap in HLA-
type with UbiLT3 (data not shown). Increased IFN-g pro-
duction in the UbiLT3 prime/boost condition was also appar-
ent when looking at the IFN-g mean fluorescence intensity
levels of the post GVAX CD8C T cells compared to the pre
GVAX and healthy control samples (Supplementary Fig. S2A).
Moreover, antigen-independent CD3 stimulation, by means of
plate-bound cross-linking using the anti-CD3 antibody OKT3
after UbiLT3 priming (UbiLT3 prime/OKT3 boost), showed
that pre GVAX, post GVAX and healthy donor CD8C T cells
were all equally equipped to produce IFN-g, while no response
was observed when cells were primed with NK DRibbles and
boosted with UbiLT3 DRibbles (Supplementary Fig. S2A).
Dividing the post GVAX samples into those patients without a
CD8C T cell response to UbiLT3 prime/boost and those with a
response, displayed significantly enhanced IFN-g levels in the
UbiLT3 prime/boost setting, but not in the UbiLT3/OKT3 or
NK/UbiLT3 control conditions (Supplementary Fig. S2B).
Of the twelve patients, we selected four patients (three
UbiLT3-responding patients and one non-responding
patient) to assess multi-functionality of the CD8C T cells by
measuring IFN-g and TNF-a co-expression. TNF-a produc-
ing cells were seen upon primary stimulation with vehicle
or NK DRibbles and boost with UbiLT3 DRibbles, though
frequencies increased under UbiLT3 DRibble prime/boost
e1466766-4 R. VAN DE VEN ET AL.
conditions in post-GVAX PBMC. In contrast, TNF-aC IFN-
gC cells as well as TNF-a¡ IFN-gC cells were specifically
induced upon UbiLT3 DRibble prime/boost (Fig. 3A). The
patient in whom no IFN-gC CD8C T cells had been
detected after in vitro stimulation previously (patient-13)
also exhibited no UbiLT3-induced TNF-a response. A simi-
lar pattern was observed looking at CD8C T cell activation
by means of CD25 expression (Fig. 3B). In concurrence
with the IFN-g data, increased expression of CD25 on
CD8C T cells upon UbiLT3 DRibble stimulation was only
observed in post GVAX PBMC and not in pre-vaccination
samples.
Interferon-g responses by CD4C T cells were analyzed;
however no UbiLT3-specific responses could be detected in
pre- or post-vaccine PBMC samples after in vitro stimula-
tion (Supplementary Fig. S3). In contrast, when DRibbles
were generated from UbiLT3 cells transduced to stably
express the CMV pp65 protein,30 a CD4C T cell response
was observed both in pre-vaccine and post-vaccine PBMC
in those patients who had apparently come in contact with
this virus (Supplementary Fig. S3A), indicating that patient
CD4C T cells can recognize DRibble-derived antigens. Using
these pp65 UbiLT3 DRibbles, we could also demonstrate
that antigens derived from DRibbles are better processed
and identified than the same antigen provided as protein or
UbiLT3-pp65 cell lysate in an overnight stimulation proto-
col using PBMC from CMV-responsive donors (Supplemen-
tary Fig. S3B and data not shown).
No functional differences between pre- and post-vaccine
CD11cC APC in presenting DRibble-derived antigens
to CD8C T cells
The prostate GVAX vaccine, through its secretion of the mono-
cyte/DC-activating cytokine GM-CSF, could potentially have
altered the functional abilities of the APC present within the
post-vaccine PBMC, such as antigen (cross)-presentation and
stimulation of T-cell proliferation. To assess qualitative differ-
ences between pre- and post-vaccine APC, pre/post crisscross
experiments were performed with selected patient samples.
Figure 2. UbiLT3 DRibble-specific CD8C T cell responses in post GVAX PBMC. 2A. IFN-g responses determined by CBA in supernatants of post-GVAX PBMC samples from
four patients harvested after 40 hours ex vivo stimulation with vehicle, NK DRibbles (NK) or UbiLT3 DRibbles (UbiLT3). PSA-DT increases or decreases are depicted. 2B.
Shown are the percentages of IFN-g producing CD8C T cells in 12 patients after 1 week in vitro stimulation of pre- (white bars) and post- (black bars) PBMC. Primary stim-
uli are as depicted on the x-axis and the secondary stimulus was 20 mg/ml UbiLT3 DRibbles. Duplicate wells were measured for each condition. The different treatment
arms (A,B,C) and the ratio in PSA-DT are indicated in the graphs. N.a. D not available. 2C. Combined CD8C IFN-g responses for UbiLT3- (left) and NK DRibble prime/boost
(right) for all patients (n D 12) and healthy donors (HD) (n D 6) tested. A 2-tailed Wilcoxin signed rank test was performed to determine a significant difference in
response between pre-and post PBMC (p < 0.007).
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These crisscross experiments showed that both pre- and post
CD11cC cells were able to present UbiLT3 DRibble-derived
antigens to CD8C T cells but that only post GVAX-vaccine
CD8C T cells were able to respond by producing IFN-g
(Fig. 4A and B). In contrast, both pre- and post CD8C T cells
were able to produce IFN-g in response to CD3 cross-linking,
confirming that pre CD8C T cells were functionally capable of
secreting IFN-g (Fig. 4A and B). The intracellular IFN-g data
were confirmed when looking at secreted IFN-g in parallel cul-
tures (Fig. 4C). In addition, in these cultures TNF-a secretion
was elevated upon prime/boost with UbiLT3 DRibbles
(Fig. 4D). TNF-a secretion was high in both pre- and post T
cell conditions upon boost with OKT3 and no TNF-a was pro-
duced when NK DRibbles were used to boost the T cells (data
not shown).
Similar crisscross results were obtained using two additional
donors with lower frequencies of DRibble-responsive IFN-g pro-
ducing CD8C T cells. In these experiments, isolated T cells were
stained with carboxyfluorescein succinimidyl ester (CFSE) prior
to co-culture with sorted, UbiLT3-stimulated, pre- or post
CD11cC cells to determine whether IFN-g producing T cells
proliferated over the course of the one week stimulation. As
shown in Fig. 5, IFN-gC CD8C T cells, 1.34% (pre-DC) and
1.91% (post-DC) of post T cells for patient-10 and 1.21% (pre-
DC) and 0.89% (post-DC) of post T cells for patient-14, showed
low CFSE levels, indicating that the IFN-g secreting cells are
within the proliferated cell fraction, while the majority of the
IFN-g negative CD8C T cells had not proliferated (Fig. 5A).
Indeed, gating specifically on IFN-g positive cells in the post
DC/post T cell conditions showed that 95% (patient-10) and
87.5% (patient-14) of all IFN-g positive cells had proliferated as
shown in the histogram plots (Fig. 5B).
Discussion
With increased recognition of the importance of the immune
system on the disease course of cancers,31-36 approaches to
study the mounting anti-cancer immunity in the absence of
accessible autologous tumor tissue for read-out purposes are
limited. It is crucial to find better ways to monitor the magni-
tude, and ideally the broadness, of therapy-generated T cell
immune responses.20 Here we show that an allogeneic, tumor-
derived autophagosome preparation derived from a mixed his-
tology adenocarcinoma/squamous cancer cell line, can be used
as a monitoring tool to detect vaccine-induced CD8C T cell
responses in PBMC from patients with prostate cancer. This
approach provides an alternative to MHC-multimer or pep-
tide-based approaches to capture the breadth of the anti-cancer
immune response, especially for those cases where screening of
autologous tumors for over-expressed proteins or neo-epitopes
is impossible or impractical due to absence or limited
Figure 3. UbiLT3-recognizing CD8T cells are poly-functional. 3A. Combined production of IFN-g and TNF-a are depicted as the percentage of CD8C T cells producing IFN-
g only (white bars), IFN-g and TNF-a (black bars) or TNF-a only (striped bars). 3B. Induction of CD25 expression on CD8C T cells, either or not in conjunction with IFN- g
release: IFN-gC CD25¡ (white bars), IFN-gC CD25C (black bars) or IFN-g¡ CD25C (striped bars). 3A, B. The upper rows show data for pre-GVAX PBMC and the lower rows
for post-GVAX PBMC. Duplicate wells were measured for each condition. Primary stimuli are as depicted on the x-axes and T cells were boosted using 20mg/ml UbiLT3
DRibbles.
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availability of material. In addition, our data confirm that mul-
tiple tumor histologies, particularly adenocarcinomas, display
substantial overlap in gene expression (e.g. NSCLC, UbiLT3
cell line, and prostate cancer), and that these overlapping char-
acteristics can be exploited for immune monitoring purposes.
Tumor mutations that provide neo-antigens the immune
system can distinguish from self-antigens have been shown to
be important in many clinical responses.13,15,37 Here we suggest
that over-expressed cancer proteins, as well as over-lapping ns-
SNVs between tumor cell lines and a cancer type can also be
exploited for immune monitoring purposes. In this study
UbiLT3 DRibbles were used to monitor responses to GVAX in
mCRPC patients. No gene expression data for these patients
was available, but by comparing the proteins in the UbiLT3
DRibbles to gene expression data for 498 PRAD patients (avail-
able through the TCGA), we found that the percent of overex-
pressed genes for which the protein is present in the UbiLT3
DRibbles ranged from 4% to 61%. A screening library of DRib-
bles from a wider range of tumor cell lines with unique gene
expression, SLiPS, DRiPs and neo-epitopes may further
increase the ability to monitor vaccine-specific responses in
patients with various types of cancer. Our group recently
Figure 4. Both pre- and post-vaccine CD11 cC cells can stimulate post vaccine CD8C T cells to recognize UbiLT3 DRibble-derived tumor antigens. 4A. Dot plots from a
pre/post crisscross experiment of one representative patient (out of 4 tested), looking at IFN-g secretion by CD8C T cells after the secondary stimulation with UbiLT3 DRib-
bles (top), NK DRibbles (middle) or plate-bound OKT3 (bottom) for the different combinations of pre- or post-DC with pre- or post T cells as indicated. 4B. Combined data
of duplicate wells analyzed for two representative patients (out of 4 tested). The graph on the left corresponds with the patient data shown in 4A. 4C. Amounts of
secreted IFN-g in ng/ml. Data are shown for the 2 patients shown in B (out of 2 tested). 4D. TNF-a secretion data in pg/ml combined for the two patient samples depicted
in 4B and C.
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showed that isolated ubiquitinated proteins, representing SLiPs
targeted for proteasomal degradation, can also serve as a prom-
ising source of tumor antigen and can be recognized by tumor-
antigen specific T cells.38 The broad range of potential epitopes
represented in a library of DRibble tumor cell lines increases
the chances of detecting neo-antigen responses in addition to
tumor antigens from SLiPs, DRiPs, overexpressed proteins and
cancer-testis antigens. GuhaThakurta et al. showed that
humoral responses against non-targeted tumor antigens could
be detected in prostate cancer patients treated with Sipuleucel-
T and correlated with improved overall survival.19 Potentially,
our monitoring approach could pick up T cell responses gener-
ated against non-targeted over-expressed proteins shared
between a patient’s prostate cancer and UbiLT3 DRibbles.
Moreover, in the case of breast and prostate cancer there is evi-
dence of immune responses against a number of shared non-
mutated proteins expressed by these cancers, encouraging the
development and testing of multivalent vaccines against non-
mutated targets.12,39 Of note, we have observed that the amount
of immune-activating danger signals contained within
DRibble-preparations varies among different cell lines. UbiLT3
DRibbles, which contain danger signals activating multiple
TLRs (TLR-2,-3,-4,-7,-9), were found to activate human mono-
cytes and DC.26 Of note, for this study DRibbles were prepared
from the LNCaP prostate cancer cell line as well. However, we
were unable to detect LNCaP responding T cells using the
described IVS culture method. This could be explained due to
low activation induction of monocytes/DCs using the LNCaP
DRibbles compared to the UbiLT3 DRibbles. Also, in a clinical
trial where mCRPC patients received GVAX in combination
with ipilimumab28 no T cell responses in IFN-g ELIspot were
observed after 10-day IVS with LNCaP cells, whereas responses
were seen using PC3 cells as stimulators (unpublished data:
personal communication with Prof. TD. de Gruijl). This sug-
gests that the LNCaP cell line might not be very immunogenic.
Therefore, our current study employed the more immune-acti-
vating, and well-characterized UbiLT3 DRibbles instead. The
presence of multiple TLR ligands in UbiLT3 DRibbles may also
explain the superior response against DRibble-derived pp65
antigen compared to loading of PBMC with pp65 protein
Figure 5. Proliferation of DRibble-responsive CD8C T cells. 5A. Dot plots show IFN-g release (y-axis) versus CFSE levels gated on CD8C T cells of post-GVAX isolated T cells
co-cultured with sorted pre-GVAX or post-GVAX UbiLT3 DRibble-stimulated DC for two patients. Post-GVAX T cells only were taken along as negative controls. 5B. Histo-
gram plots show CFSE levels of T cells only and gated IFN-g¡ CD8C and IFN-gC CD8C T cells from co-cultures of post-GVAX UbiLT3 DRibble-stimulated DC and post-
GVAX T cells.
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(Fig. S3B). The fact that the response against the short peptide
was much higher than the response against pp65 DRibbles in
one of the two patients tested, might just reflect a total pp65
peptide concentration difference since DRibbles will also con-
tain other antigens or the lack of need for antigen-uptake and
processing of short peptide sequences. In a separate study, we
have optimized the protocol for viral antigen recognition using
DRibbles.30
To date, little data are available on the magnitude of tumor-
specific CD8C T cell responses in patients with prostate cancer,
when looking at intracellular cytokines and monitoring for
more than one antigen. However, there are reports of vaccine-
induced, antigen-specific CD8C T cell responses detected by
IFN-g ELIspot against specific peptide pools.40 In the majority
of the clinical trials, the focus is on serum PSA responses,
humoral responses as well as T cell activation or CD4-
responses.19,28,29,41-44 No autologous tumors were available
from the patients from this trial, making it impossible to test
whether the CD8C T cells recognizing antigens in the UbiLT3
DRibble vaccine could also recognize and kill autologous tumor
cells. The lack of primary tumor also prevented the search for
patient-specific neo-epitopes and CD8C T cells recognizing
such epitopes.13,37,45 In ongoing research, we are looking for
ways to evaluate the tumor-killing abilities of DRibble-respon-
sive T cells in other cancer types where autologous tumor cells
are available. Also, we aim to perform comparable monitoring
studies in a cohort of patients in whom objective clinical
responses were observed after therapy to determine whether
the presence or magnitude of DRibble-responsive CD8C T cells
correlate with improved clinical outcome. Had the patients in
our trial received checkpoint inhibitors in conjunction with
prostate GVAX, more clinical responses might have been
obtained. It could thus be that the T cells, detected (and
expanded) in our in vitro assay, were present in vivo, but could
not effectively eliminate cancer cells due to the suppressive
tumor microenvironment.
In conclusion, our data show that an autophagosome-based
vaccine preparation, UbiLT3 DRibbles, shares tumor antigens
with prostate cancers and can be used to detect vaccine-
induced CD8C T cell responses. We postulate that tumor-cell
derived DRibble preparations, due to their content of SLiPs
and DRiPs22,23 as well as danger signals,27 could be used as a
practical immune monitoring tool for multiple types of cancers
to assess the magnitude of therapy-induced T cell responses
and may be useful as a vaccine for patients with prostate cancer.
Patients and Methods / Materials and Methods
Clinical trial
A total of seventeen patients with mCRPC were enrolled to
receive the prostate GVAX vaccine at our institute. This was a
single center, US Department of Defense-funded clinical trial
open at Providence Cancer Center between 2005 and 2007
(NCT00122005). An apheresis product was obtained from all
patients before treatment (pre sample) and from 12/17 patients
at week 12 (post sample). The 5 patients that went off-study
before the week-12 apheresis were not included in the current
study. Patients were randomized into three cohorts; patients
received up to 12 prostate GVAX vaccines (two week intervals)
with either no additional chemotherapy (cohort A), 350 mg/m2
cyclophosphamide on days 1–3 (cohort B) or 350 mg/m2 cyclo-
phosphamide and 20 mg/m2 fludarabine on days 1–3 (cohort
C). Men receiving nonmyeloablative chemotherapy received
hematopoietic reconstitution with an adoptive transfer of an
autologous apheresis product 2 days following completion of
nonmyeloablative chemotherapy (See supplementary Fig. S1
for trial flow chart).
Collection of patient- and healthy donor blood samples
Leukapheresis products or blood draws were also obtained
from anonymous healthy volunteers. Written informed consent
was obtained from all patients and healthy donors in accor-
dance with the Declaration of Helsinki. PBMCs were isolated
using a density gradient separation method and were cryopre-
served and stored in a monitored LN2 storage system under
standardized operating procedures. Approval was obtained
from the institutional review board (IRB) of Providence Port-
land Medical Center for all studies.
Protein expression and sequencing analysis
The UbiLT3 cell line used was developed at the Earle A.
Chiles Research Institute and the UbiLT3 DRibble vaccine
was performed by UbiVac. The Cell line identity testing
and confirmation that it was absent from specified patho-
gens, was performed by BioReliance. Proteins in the UbiLT3
DRibble vaccine were TMT labeled and identified by mass
spectrometry (OHSU Proteomics Core) on a Thermo Scien-
tific Orbitrap Fusion, 2D-RPRP with 18 fractions, 120 min/
fraction. The mass spectrometry data was processed with
SEQUEST/PAWS using SPROT_HUMAN database. 5286
proteins were detected with a minimum of 2 unique pepti-
des/protein. Proteins detected in UbiLT3 were screened
against 498 prostate adenocarcinoma patient samples
(TCGA PRAD, Provisional) and the Cancer Cell Line Ency-
clopedia in The Cancer Genome Atlas (TCGA) database
using the cBio Portal (http://www.cbioportal.org/public-por
tal/) for genes with expression up-regulated (z score > 2) in
tumor compared to the patients’ normal tissue.
UbiLT3 exomic DNA was sequenced at 30x read depth
(Otogenetics – Illumina Iibrary prep/QC; Agilent human V4/
V5, 51 Mb capture/QC; HiSeq2000 NGS). Ns-SNVs were deter-
mined with respect to the hg19 reference genome. Publically
available VCF files for 307 Prostate adenocarcinoma patients
from the TCGA database (https://tcga-data.nci.nih.gov/tcga/ –
from the PRAD study using the BI Mutation calling pipeline)
were used to identify ns-SNVs present only in the tumor sam-
ple compared to the patient’s normal tissue. Ns-SNVs unique
to the tumor were compared to UbiLT3 ns-SNVs to identify
shared ns-SNVs using the CLC Genomics Workbench 7.5.
The prostate GVAX vaccine consisted of PC3 and LNCaP cell
lines. PC3 and LNCaP exome sequence data were obtained from
the Cancer Cell Line Encyclopedia database (broadinstitute.org/
ccle/home). Ns-SNVs for PC3 and LNCaP were determined with
respect to hg19 and compared to unique ns-SNVs in the 307 pros-
tate adenocarcinoma tumors described above. VCF files for PC3
(6407 ns-SNVs (reference hg19); 748 ns-SNVs filtered with
(hg19) dbsnp (common) variants) and LNCaP (11938 ns-SNVs
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(reference hg19); 3802 ns-SNVs filtered with (hg19) dbsnp (com-
mon) variants) cell lines were compared to the TCGA PRAD pro-
visional database for shared ns-SNVs. Shared ns-SNVs between
prostate tumors and PC3 or LNCaP were compared to UbiLT3 to
identify ns-SNVs shared between the tumors and PC3/UbiLT3 or
LNCaP/UbiLT3.
In vitro stimulation of PBMC with DRibbles
Autophagosome-enriched DRibbles were prepared from the
UbiLT3 cell line, primary kidney cells or UbiLT3 cells transduced
to stably express the CMV pp65 protein or GFP control protein
(plasmids p6 A-O’PB-IPWS-pp65 and pmax-GFP provided by
Dr. Hong-Ming Hu), similarly to the preparation of the clinical-
grade DPV-001 vaccine, with minor alterations to what was
described previously for the preparation of mouse DRibbles.22,23
Briefly, tumor cells were treated with 100 nM bortezomib (Vel-
cade) (Millenium) and 10 mM NH4Cl (Hospira, 0409-6043-01)
for 24 hours in a 5% CO2 incubator at 37C. At 24 hours post
treatment, cells were harvested and disrupted using a Bioruptor
(Diagenode). Cells were centrifuged at 625xg (4C) to pellet and
discard the cellular debris. The supernatant was centrifuged at
2000xg (4C) to pellet larger protein aggregates and remaining cel-
lular debris. The supernatant was centrifuged at 12,000xg (4C)
for 20 minutes. The final DRibble pellet was resuspended in 6%
hetastarch, protein content measured by BCA (Pierce, 23277) and
DRibbles brought to 1 mg/mL.
Pre- and post-vaccine PBMC were thawed in warm HBSS
supplemented with 1% human serum albumin (HSA; Baxter,
2G0201), were rested for 15 minutes at RT and were stimulated
for 18–20 h with 75mg/ml UbiLT3 or control normal kidney
(NK) DRibbles or a corresponding volume (75ml/ml) of 6%
hetastarch (vehicle) (Hospira, 00409-7248-03) in sterile poly-
propylene 4 ml tubes, in a maximum volume of 1 ml (4 million
cells/ml) in X-Vivo 15 media (Lonza, 04–418Q). Cells were cul-
tured at 37C and 5% CO2. After 18–20 h, cells were washed
and taken up in media consisting of 50% X-Vivo 15 and 50%
RPMI 1640 supplemented with 1.25% HSA, 2 mM L-glutamine
(Lonza, BW17-605E), 1 mM sodium-pyruvate (Lonza, BW13-
115E) and 50 mg/ml gentamicin-sulfate (Lonza, 17–518Z)
(RPMI/HSA). Cells were transferred to 96-well round-bottom
plates at a concentration of 1 million cells/ 200ml per well in
duplicate. On day 4, 5 cU/ml IL-2 (Prometheus, NDC 65483-
116-07) was added. On day 7, cells from each well were divided
into 3 wells, and re-stimulated with plate-bound anti-CD3
(OKT3; Miltenyi Biotec, 170-076-124) as positive control
(200ml of 10 mg/ml per well coated for 4 hours at 37 C or for
18 hrs at 4C), 20mg/ml NK DRibbles and 20mg/ml UbiLT3
DRibbles. After 5 hours, 5mg/ml Brefeldin-A (Sigma-Aldrich,
B7651) was added and intracellular cytokine analysis was per-
formed 12 hours later. For the analysis of secreted cytokines in
the culture supernatant, cells were treated similarly as above,
unless indicated otherwise in the text, without the addition of
Brefeldin-A. Supernatants were harvested 18–20 hours after the
start of the re-stimulation and stored at -80C until further use.
Criss-cross IVS experiment
Pre- and post-PBMC were stimulated for 20 h with vehicle or
UbiLT3 DRibbles as described above, after which CD11cC cells
were isolated by flow cytometric sorting (CD11c PerCP-
eFluor710, eBiosciences: 46-0116-42; clone 3.9) from the DRib-
ble-stimulated samples using a custom-build BD FACS Aria II
(BD Biosciences) and T cells were isolated by means of
untouched isolation from the vehicle cultured pre- and post
PBMC using the pan T cell isolation kit II (Miltenyi Biotec:
130-096-535). Next, 50,000 CD11cC cells in 100ml RPMI/HSA
and 200,000 T cells in 100ml X-Vivo15 were co-cultured for
7 days, combining pre- or post CD11cC cells with pre- or post
T cells. Unsorted vehicle- and UbiLT3 DRibble stimulated
PBMC samples were taken along as assay controls. After
7 days, cultures were re-stimulated with UbiLT3 DRibbles, NK
DRibbles or OKT3 as indicated above and intracellular IFN-g
production and overall cytokine secretion were determined
18–20 hours later.
Magnetic-bead isolated pre- and post T cells were taken up
in HBSS supplemented with 5% FBS at a concentration of 2 mil-
lion cells/ml and were incubated with 1mM CFSE (Invitrogen,
C34554) in a 37C water bath for 7 minutes. Cells were washed
three times with HBSS/FBS before resuspending in X-vivo15
media and the addition of 200,000 CFSE-labeled T cells to
50,000 UbiLT3 stimulated pre- or post CD11cC cells. Prolifera-
tion was assessed at the time of intracellular cytokine staining
on day 8 after antigen re-stimulation. For intracellular cytokine
staining protocol see below.
Flow cytometry analysis of surface markers
and intracellular cytokines
For intracellular cytokine analysis, re-stimulated cells were har-
vested and stained for surface markers and viability using antibod-
ies directed against CD3 (V500; BD Pharmingen: 560770; clone
SP34-2), CD8 (BV421; BD Horizon: 562428; clone RPA-T8),
CD4 (PE-Cy7; BD Pharmingen: 557852; clone SK3/Leu3a), CD14
(PE-TR; Invitrogen: MHCD1417; clone TuK4), CD25 (APC; Mil-
tenyi Biotec: 130-098-213; clone 4E3) and yellow fixable live-dead
dye (Invitrogen). After surface staining, cells were permeabilized
and fixed using the BD fix/perm kit and incubated with anti-IFN-
g (PE; BD Pharmingen: 554701; clone B27) labeled antibodies for
30 minutes at 4C. In some experiments cells were stained for
intracellular TNF-a (APC; BD Pharmingen: 340534; clone
6401.1111) and not surface CD25. Cells were washed and ana-
lyzed on the Aria II flow cytometer. When feasible, 30,000 events
were taken up for each tube. Analyses were performed using
FlowJo software version 9.7.6 (Treestar).
Supernatant cytokine analysis by cytometric bead array
A Th1/Th2 cytometric bead array (CBA) was used for the
detection of secreted IFN-g, TNF-a, IL-2, IL-5, IL-10 and IL-4
(BD Biosciences: 550749). A BD HTS plate-reader attached to
an LSR II BD flow cytometer running FACS Diva software was
used for automated acquiring of the samples, acquiring 2000
bead events per well. BD Cytometric Bread Array 1.4 was used
to analyze the data.
Statistical analysis
Prism6 software was used to generate graphs and perform sta-
tistical analysis. For the comparison of IFN-g producing CD8C
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T cells between pre- and post PBMC, a Wilcoxon matched-
pairs signed rank test (two-sided) was used, based on nonpara-
metric distribution. Conditions were considered statistically
significant when p < 0.05.
Abbreviations
APC antigen presenting cell
CFSE carboxyfluorescein succinimidyl ester
DAMPs danger-associated molecular patterns
DC dendritic cell
DRiPs defective ribosomal products
HLA human leukocyte antigen
PBMC peripheral blood mononuclear cells
MHC major histocompatibility complex
PRAD prostate adeno
ns-snv non-synonymous single-nucleotide variant
PSA-DT prostate-specific antigen doubling time
SLiPs short lived proteins
TAA tumor-associated antigen
TCGA The Cancer Genome Atlas
WES whole exome sequencing
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